Glaukos Corporation (GKOS)
| Market Cap | 9.21B +57.2% |
| Revenue (ttm) | 551.35M +36.3% |
| Net Income | -189.33M |
| EPS | -3.29 |
| Shares Out | 58.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 375,760 |
| Open | 153.21 |
| Previous Close | 155.39 |
| Day's Range | 152.06 - 157.77 |
| 52-Week Range | 73.16 - 161.53 |
| Beta | 0.75 |
| Analysts | Strong Buy |
| Price Target | 165.00 (+5.21%) |
| Earnings Date | Jul 29, 2026 |
About GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ... [Read more]
Financial Performance
In 2025, Glaukos's revenue was $507.44 million, an increase of 32.33% compared to the previous year's $383.48 million. Losses were -$187.69 million, 28.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price target is $165.0, which is an increase of 5.21% from the latest price.
News
Glaukos price target raised to $175 from $170 at Stifel
Stifel raised the firm’s price target on Glaukos (GKOS) to $175 from $170 and keeps a Buy rating on the shares. Following iDose survey work, the firm sees probability-weighted 2027…
Glaukos price target raised to $180 from $160 at Truist
Truist raised the firm’s price target on Glaukos (GKOS) to $180 from $160 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Glaukos price target raised to $164 from $162 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $164 from $162 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos price target raised to $175 from $162 at Citi
Citi raised the firm’s price target on Glaukos (GKOS) to $175 from $162 and keeps a Buy rating on the shares. For Q2 earnings season, given “the skittish trading environment,”…
Glaukos initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Glaukos (GKOS) with a Buy rating and $168 price target Glaukos pioneered and still leads the global micro-invasive glaucoma surgery market that it created with…
Glaukos completes patient enrollment in Phase 2 study of GLK-321
Glaukos (GKOS) announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. “Completion of enrollment in this Phase 2 study mar...
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos price target raised to $150 from $136 at Needham
Needham raised the firm’s price target on Glaukos (GKOS) to $150 from $136 and keeps a Buy rating on the shares. The firm notes that while it wants to see…
Glaukos Transcript: Truist Securities MedTech Conference 2026
iDose continues to drive strong glaucoma growth, with reimbursement hurdles easing and a large eligible patient pool, even as LCD proposals introduce new requirements. Epioxa's launch is outperforming expectations, supported by robust commercial access and a focused care network.
Glaukos price target raised to $162 from $140 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Glaukos (GKOS) to $162 from $140 and keeps a Buy rating on the shares. The firm sees “substantial runway” for…
Glaukos Transcript: Jefferies Global Healthcare Conference 2026
Management is actively addressing concerns with the draft LCD, aiming to align policy with clinical practice and maximize patient access to iDose. Epioxa's launch is progressing ahead of expectations, with strong payer coverage and a transition plan from Photrexa. The company is confident in its pipeline and market position.
Glaukos Transcript: 46th Annual William Blair Growth Stock Conference
The company is driving growth through innovative glaucoma and keratoconus therapies, expanding its product pipeline, and shifting treatment paradigms toward interventional and dropless solutions. Strong financials, new product launches, and a focus on in-office procedures position it for continued expansion.
Glaukos Transcript: AGM 2026
The meeting featured the election of two directors, strong approval of executive compensation, and ratification of the auditor, all by wide margins. No questions were raised by stockholders during the Q&A session.
Glaukos pullback due to concerns about iDose LCD, says William Blair
William Blair notes that Glaukos (GKOS) shares were weak on Friday, May 22, which the firm attributes to investor concerns on last week’s proposed Local Coverage Determination, or LCD, for…
Glaukos Transcript: Stifel 2026 Virtual Ophthalmology Forum
Management is confident that recent restrictive LCD proposals for iDose will be amended through advocacy and clinical evidence, with final impacts likely in 2027. Despite current uncertainty, long-term growth prospects remain strong due to a large addressable market and multiple growth drivers.
Glaukos price target raised to $162 from $141 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $162 from $141 and keeps a Buy rating on the shares. The company’s product pipeline is among the best in…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos Slides: Investor presentation
Glaukos has posted slides in relation to its latest quarterly earnings report, which was published on May 1, 2026.
Glaukos price target raised to $153 from $134 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Glaukos (GKOS) to $153 from $134 and keeps a Buy rating on the shares. Glaukos reported strong Q1 results with revenue and…
Glaukos price target raised to $170 from $160 at Stifel
Stifel analyst Thomas Stephan raised the firm’s price target on Glaukos (GKOS) to $170 from $160 and keeps a Buy rating on the shares.
Glaukos price target raised to $140 from $120 at JPMorgan
JPMorgan raised the firm’s price target on Glaukos (GKOS) to $140 from $120 and keeps an Overweight rating on the shares.
Glaukos price target raised to $136 from $127 at Needham
Needham raised the firm’s price target on Glaukos (GKOS) to $136 from $127 and keeps a Buy rating on the shares.
Glaukos price target raised to $141 from $131 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $141 from $131 and keeps a Buy rating on the shares. The company’s Glaucoma and iDose revenue exceeded the firm’s…
Glaukos price target raised to $140 from $135 at Citi
Citi raised the firm’s price target on Glaukos (GKOS) to $140 from $135 and keeps a Buy rating on the shares.